Additional Insights
Characterizing the disposition of lipid nanoparticle (LNP) formulations is a required step in the development of many Advanced Therapeutics and Complex Biologics. Applying proven intelligence in preclinical toxicology is how our scientific teams accelerate these next-generation therapies toward successful IND submissions. A standard preclinical template does not exist for these assets; each program requires a data-driven strategy tailored to the specific LNP composition and RNA payload.
The infrastructure required to support these programs must adapt to their complexity. “The value chain is diversifying… we are no longer just dealing with a pill in a bottle. We are dealing with living cells, with viral vectors, and the infrastructure has to adapt to that reality.” This is especially true for LNP systems, where minor formulation changes can produce significant shifts in biodistribution.
Scientific literature confirms that helper lipid structure is a key determinant of LNP delivery. Preclinical evaluations have shown that formulations containing certain helper lipids preferentially target the liver, while others direct the LNP to the spleen. This organ-specific tropism has direct implications for both efficacy and the design of subsequent toxicology programs.
A well-designed LNP pharmacokinetic study includes:
- Selection of a nonhuman primate model with an immune system that closely mirrors the human response.
- Quantification of the LNP and its payload in plasma and tissues, executed under phase-appropriate GCLP guidelines.
- Comprehensive tissue collection protocols to accurately map biodistribution.
- Execution within a GLP-compliant environment to support regulatory filings.
This detailed characterization provides the data necessary to de-risk clinical translation. Understanding where an LNP formulation accumulates allows sponsors to move forward with confidence, backed by a team whose work has resulted in a 100% successful IND rate since 2019. This legacy, now operating as Franklin Biolabs since our 2024 launch, continues to accelerate programs from candidate to IND within 18-24 months. For more information on our comprehensive support, please see our parent Preclinical | Translational Services hub.